Helped by the introduction of new products, women’s health-care company Warner Chilcott (WCRX) expects to book a fiscal 2011 profit in line with Wall Street estimates.

The specialty pharmaceutical company sees full-year earnings in the range of $3.45 to $3.55 a share, meeting average analyst estimates polled by Thomson Reuters of $3.50 a share.

The Dublin-based company anticipates revenue in the range of $2.7 billion to $2.8 billion, in line with the Street’s view of $2.77 billion.

The outlook reflects its November warnings of a “dramatic decline” in sales of Actonel in Western Europe, partially offset by strong anticipated growth of promoted products in the U.S., including two launched last month.

Follow Jennifer Booton on Twitter at @Jbooton